RDHL vs IRWD

For growth investors, RedHill Biopharma Ltd.

(RDHL) is the stronger pick with 23. 2% revenue growth year-over-year, versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). Ironwood Pharmaceuticals, Inc. (IRWD) offers the better valuation at 28. 1x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Ironwood Pharmaceuticals, Inc. (IRWD) a "Hold" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ironwood Pharmaceuticals, Inc.

(IRWD) delivered a total return of -61. 6%, compared to -100. 0% for RedHill Biopharma Ltd. (RDHL). Over 10 years, the gap is even starker: IRWD returned -58. 7% versus RDHL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RedHill Biopharma Ltd.

(RDHL) is the lower-risk stock at 1. 30β versus Ironwood Pharmaceuticals, Inc. 's 2. 62β — meaning IRWD is approximately 102% more volatile than RDHL relative to the S&P 500.

By revenue growth (latest reported year), RedHill Biopharma Ltd.

(RDHL) is pulling ahead at 23. 2% versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). Over a 3-year CAGR, IRWD leads at -10. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ironwood Pharmaceuticals, Inc.

(IRWD) is the more profitable company, earning 8. 1% net margin versus -102. 8% for RedHill Biopharma Ltd. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -181. 7% for RDHL. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, RedHill Biopharma Ltd.

(RDHL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 30)). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RDHL: -100. 0%, IRWD: -58. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RDHL is a small-cap high-growth stock; IRWD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.